Clinical studies comparing the response and side effects of various opioids have not been
able to show robust differences between drugs. Hence, recommendations of the regulatory …

This paper is the 28th consecutive installment of the annual review of research concerning
the endogenous opioid system, now spanning over a quarter-century of research. It …

Breakthrough cancer pain (BTcP) is an episode of severe pain that “breaks through” a
period of persistent pain at least partly controlled by a stable opioid regimen. Although …

Morphine is a widely used opioid for treatment of moderate to severe pain, but large
interindividual variability in patient response and no clear guidance on how to optimise …

The μ-opioid receptor (OPRM1) is the principal receptor target for both endogenous and
exogenous opioid analgesics. There are substantial individual differences in human …

As the major psychoactive agent in opium and direct precursor for heroin, morphine is a
historically critical molecule in chemical neuroscience. A structurally complex phenanthrene …

Introduction Optimal pain management is crucial to the postoperative recovery process. We
aimed to evaluate the efficacy and safety of intravenous oxycodone with intravenous …

Oxycodone is a semisynthetic opioid analgesic that is increasingly used for the treatment of
acute, cancer, and chronic non-malignant pain. Oxycodone was synthesized in 1917 but its …

Abstract Background and Objectives Obesity and opioid use for chronic pain in obese
individuals are both important public health concerns. The pharmacokinetics of oral …

Background Oxycodone is a µ-opioid receptor agonist, the global use of which has
increased vigorously during the past decade. The pharmacokinetic data of oxycodone …